



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

## Non-COVID-19 intensive care admissions during the pandemic

**Citation for published version:**

McLarty, J, Litton, E, Beane, A, Pilcher, DV, Salluh, JIF, Haniffa, R & Lone, NI 2023, 'Non-COVID-19 intensive care admissions during the pandemic: A multinational registry-based study', *Thorax*.  
<https://doi.org/10.1136/thorax-2022-219592>

**Digital Object Identifier (DOI):**

[10.1136/thorax-2022-219592](https://doi.org/10.1136/thorax-2022-219592)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Thorax

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# Non-COVID-19 intensive care admissions during the pandemic: A multinational registry-based study

**Type of manuscript: Original article**

## Authors

**Writing committee, on behalf of LOGIC (Linking of Global Intensive Care):** Joshua McLarty<sup>1,2</sup>, Edward Litton<sup>3,4</sup>, Abigail Beane<sup>5,6</sup>, David Pilcher<sup>1,2</sup>, Jorge I. F. Salluh<sup>7,8</sup>

**Additional authors:** Diptesh Aryal<sup>9</sup>, Michael Bailey<sup>10</sup>, Mohamed Basri Mat Nor<sup>11</sup>, Stepani Bendel<sup>12</sup>, Gaston Burghi<sup>13</sup>, Steffen Christensen<sup>14</sup>, Christian F. Christiansen<sup>15</sup>, Dave A. Dongelmans<sup>16,17</sup>, Ariel L Fernández<sup>18</sup>, Aniruddha Ghose<sup>19</sup>, Roselind Hall<sup>20</sup>, Rashan Haniffa<sup>5,6</sup>, Madiha Hashmi<sup>21</sup>, Satoru Hashimoto<sup>22,23</sup>, Nao Ichihara<sup>24</sup>, Bharath Kumar Tirupakuzhi Vijayaraghavan<sup>25,26</sup>, Nazir I. Lone<sup>27</sup>, Maria del Pilar Arias López<sup>18,28</sup>, Hiroshi Okamoto<sup>29</sup>, Dilanthi Priyadarshani<sup>30</sup>, Matti Reinikainen<sup>12</sup>, Marcio Soares<sup>7</sup>

**Conflicts of interest and Financial Support:** Dr D Pilcher and Dr E Litton are members of the Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcome and Resources Evaluation management committee. Abigail Beane is funded by Wellcome. Drs Salluh and Soares are co-founders and shareholders of Epimed Solutions, a healthcare cloud-based analytics company. They are also supported in part by individual research grants from CNPq and FAPERJ. Dr Bendel is the current chair and Dr Reinikainen the past chair of the Finnish Intensive Care Consortium (both unpaid). Dr. D.A.Dongelmans is unpaid chair of NICE foundation. Nao Ichihara's primary affiliation is the Department of Healthcare Quality Assessment, which is a social collaboration department at the University of Tokyo supported by National Clinical Database, Johnson & Johnson K.K., and Nipro corporation. Dr Tirupakuzhi Vijayaraghavan is the National Coordinator for the Indian Registry of Intensive care (IRIS) and is supported for 0.5 FTE by funding from the Wellcome Trust, U.K. The remaining authors have no conflicts of interest to declare.

## Affiliations:

1. The Alfred Hospital, Melbourne, Australia
2. Monash University, Melbourne, Australia
3. St John of God Hospital Subiaco, Perth, Australia
4. School of Medicine, University of Western Australia, Perth, Australia
5. Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand
6. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom
7. D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil
8. Postgraduate Program of Internal Medicine, Federal University of Rio de Janeiro, (UFRJ), Rio de Janeiro, Brazil
9. Nepal Intensive Care Research Foundation (NICRF), Nepal
10. Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University
11. Department of Anaesthesiology and Intensive Care, Kulliyah (School) of Medicine, International Islamic University Malaysia
12. Department of Anaesthesiology and Intensive Care, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland

13. Hospital Maciel, Montevideo, Uruguay
14. Department of Anesthesia and Intensive Care Medicine, Aarhus University Hospital, Aarhus, Denmark
15. Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
16. Amsterdam UMC, University of Amsterdam, Department of Intensive Care Medicine, Amsterdam, the Netherlands
17. National Intensive Care Evaluation (NICE) foundation, Amsterdam, the Netherlands
18. Argentine Society of Intensive Care. SATI-Q Program. Buenos Aires, Argentina
19. Department of Medicine, Chittagong Medical College, Bangladesh
20. Public Health Scotland, Edinburgh, UK
21. Ziauddin University, Sindh, Pakistan
22. Division of Intensive Care, Department of Anesthesiology & Intensive Care Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
23. Japanese Intensive care PATient Database (JIPAD)
24. The University of Tokyo, Tokyo, Japan
25. The George Institute for Global Health, New Delhi, India
26. Department of Critical Care Medicine, Apollo Main Hospital, Chennai, India
27. Usher Institute, University of Edinburgh, UK
28. Hospital de Niños R Gutierrez, PICU. Buenos Aires, Argentina
29. St. Luke's International Hospital, Tokyo, Japan
30. NICS-MORU, Colombo, Sri Lanka

**Corresponding author:**

Joshua McLarty

The Alfred Hospital, Melbourne, Australia

Monash University, Melbourne, Australia

Correspondence: [josh.m.c.mclarty@gmail.com](mailto:josh.m.c.mclarty@gmail.com)

Word count: 3373

**Abstract***Background*

The COVID-19 pandemic resulted in a large number of critical care admissions. While national reports have described the outcomes of COVID-19 patients, there is limited international data of the pandemic impact on non-COVID-19 patients requiring intensive care treatment.

*Methods*

We conducted an international, retrospective cohort study using 2019 and 2020 data from 11 national Clinical Quality Registries covering 15 countries. Non-COVID-19 admissions in 2020 were compared to all admissions in 2019, pre-pandemic. The primary outcome was intensive care unit (ICU) mortality. Secondary outcomes included in-hospital mortality, and standardised mortality ratio (SMR). Analyses were stratified by the country income level(s) of each registry.

*Findings*

Amongst 1,642,632 non-COVID-19 admissions, there was an increase in ICU mortality between 2019 (9.3%) and 2020 (10.4%), odds ratio (OR)=1.15 (95% CI 1.14–1.17,  $p<0.001$ ). Increased mortality was observed in middle-income countries (OR 1.25 95% CI 1.23-1.26), while mortality decreased in high-income countries (OR=0.96 95% CI 0.94-0.98). Hospital mortality and SMR trends for each registry were consistent with the observed ICU mortality findings. The burden of COVID-19 was highly variable, with COVID-19 ICU patient-days per bed ranging from 0.4 to 81.6 between registries. This alone did not explain the observed non-COVID-19 mortality changes.

*Interpretation*

Increased ICU mortality occurred amongst non-COVID-19 patients during the pandemic, driven by increased mortality in middle-income countries, while mortality decreased in high-income countries. The causes for this inequity are likely multi-factorial, but healthcare spending, policy pandemic responses, and ICU strain may play significant roles.

*Funding*

No funding was sought for this publication.

**Key messages***What is already known on this topic*

The COVID-19 pandemic has increased the global healthcare burden and has been associated with an excess death rate in many countries. Most studies are limited to COVID-19 patients, and single countries or regions. The few international comparisons are largely limited to high-income countries, while the burden of COVID-19 infections has disproportionately affected low- and middle-income countries.

*What this study adds*

To our knowledge, this is the first international comparison of critically ill non-COVID-19 patients throughout the pandemic. Overall mortality amongst non-COVID-19 patients increased, driven by increased mortality in Middle-Income Countries (MICs), while mortality decreased in High-Income Countries. The burden of COVID-19 care may be associated with worse outcomes in these countries, but alone does not explain the differences in mortality. The increase in non-COVID-19 mortality is partly responsible for the excess death rate observed throughout the pandemic.

*How this study might affect research, practice, or policy*

The pandemic has been associated with increased non-COVID-19 mortality and has disproportionately impacted ICU mortality in countries with lower income levels. Further research is required to examine the association between the pandemic and non-COVID-19 deaths, as well as causes of the observed inequity, and to find what can best be done to combat the challenges facing the delivery of intensive care in MICs and LICs, especially as the pandemic continues.

## Introduction

The COVID-19 pandemic has had a broad healthcare impact, resulting in high intensive care unit (ICU) admission rates<sup>1</sup> and disruption to ICU service delivery.<sup>2</sup> Indirect effects have included decreases in cancer diagnosis rates,<sup>3</sup> transplant surgeries,<sup>4</sup> and coronary artery percutaneous interventions.<sup>5</sup> An excess death rate above the reported COVID-19 death rate has been observed, largely attributed to unreported COVID-19 cases.<sup>6, 7</sup>

Outcomes of patients requiring intensive care treatment due to severe COVID-19<sup>1, 7-13</sup> are dependent on patients' characteristics (e.g. severity of illness, age and co-morbidities), and organizational factors including ICU strain, surge capacity, and geographical location within countries.<sup>1, 9, 14, 15</sup> Whether the COVID-19 pandemic changed the characteristics or outcomes of non-COVID-19 patients requiring intensive care treatment remains uncertain.

The primary aim of this study was to describe the mortality for non-COVID-19 ICU patients during the pandemic, compared to the pre-pandemic period, using data from national Clinical Quality Registries (CQRs). The hypothesis was that the pandemic resulted in increased mortality of non-COVID-19 ICU patients.

## Methods

### *Design*

This was an international, retrospective cohort study using routinely collected, de-identified, aggregated patient-level data from ICU CQRs over the 2019 and 2020 calendar years. As COVID-19 was first reported in China in December 2019 and the first cases outside China occurred in January 2020,<sup>16</sup> all ICU admissions in the 2019 calendar year were considered non-COVID-19. These were compared to calendar year 2020, for which all contributing registries were considered to be affected by the COVID-19 pandemic regardless of the date of the first confirmed COVID-19 case in each CQR.

### *Setting*

Eligible national CQRs were those that recorded data on patients admitted to adult ICUs in 2019 and 2020 and were able to identify the cohort of patients within the registry that were admitted with COVID-19. CQRs were identified through the 'Linking Of Global Intensive Care' initiative (LOGIC).<sup>17</sup> Representatives from 15 additional national CQRs were contacted directly, of whom three agreed to participate. Further information on each of the participating registries can be found in the supplementary appendix. The project received approval as a low-risk project from the Human Research Ethics Committee of Alfred Health, Melbourne, Australia (HREC 131/21) and from the ethics committee of the Instituto D'or de Pesquisa e Ensino, Rio de Janeiro, Brazil [Number: 44181021.3.0000.5249].

### *Variables*

CQR data included characteristics of the CQRs (size, national coverage, available ICU beds, proportion of public and private hospitals), and aggregated patient data by patient group – COVID-19, non-COVID-19, and total for 2019 and 2020.

Population data, Gross Domestic Product (GDP), country income category, and healthcare expenditure were sourced from The World Bank.<sup>18</sup> Country COVID-19 diagnoses rates were sourced from the Oxford COVID-19 Government Response Tracker.<sup>19</sup>

The primary outcome was ICU mortality, a metric available from all contributing CQRs. Secondary outcomes included ICU length of stay (LOS), mechanical ventilation, hospital mortality and standardised mortality ratio (SMR). Expected hospital mortality used for SMR was based on the illness severity score models (e.g. APACHE-II, SOFA, SAPS3) for each

1  
2 CQR. Further detail on expected in-hospital mortality can be found in the supplementary  
3 appendix.  
4

#### 5 *Statistical analysis*

6 CQRs provided only aggregate data, no individual patient data were analysed. The impact of  
7 the COVID-19 pandemic was assessed by temporal comparison of non-COVID-19 ICU  
8 admissions within each region in 2020 compared to 2019 and by comparison of patients  
9 admitted to ICUs between regions that were differentially affected by the pandemic in 2020.  
10  
11

12 Descriptive analyses were provided on registry coverage, admission numbers, admission  
13 source, age, sex, mechanical ventilation, illness severity (based on local and international  
14 severity of illness scores), length of stay, ICU mortality, and hospital mortality. SMRs  
15 were calculated as the ratio of the observed in-hospital mortality to the expected in-hospital  
16 mortality for each CQR.  
17

18 The available registry-level data were aggregated into internationally representative statistics,  
19 using a fixed-effect model with inverse-variance weighting to account for differences between  
20 countries. The statistical analysis was performed using the Review Manager 5 (RevMan5)  
21 software<sup>20</sup>. Means with standard deviations were used when appropriate. Odds ratios for  
22 dichotomous variables and mean differences for continuous variables were used to compare  
23 between years. Chi-square tests of significance were used for categorical variables.  
24  
25

26 ICU admission numbers for each registry were indexed to population size and total COVID-  
27 19 cases in the community, extrapolating the available data based on the coverage of each  
28 registry within each country. Analysis of outcomes was stratified by country income level.  
29 Missing data were not imputed.  
30

#### 31 **Results**

32 There were 11 participating registries representing 15 countries in four continents. A  
33 comparison of the key features of the contributing registries can be found in the supplementary  
34 appendix. Four countries represented (Bangladesh, India, Nepal, and Pakistan) were Lower-  
35 Middle Income Countries (LMICs), three (Brazil, Argentina, Malaysia) were Higher-Middle  
36 Income Countries (HMICs), and the remaining eight countries were high income countries  
37 (HICs).  
38  
39

40 Data were provided for more than 1.7 million ICU admissions across 2082 ICUs. The mean  
41 age of patients admitted to the ICU was 61.3 years (SD 19.1), with substantial variation  
42 between registries (range 51.5 in the Collaboration for Research, Implementation and Training  
43 in Intensive Care in Asia (CCA) registry to 64.0 in Japan). Males accounted for 54.8% of  
44 patients (range 51.4% in Brazil to 63.8% in Finland). Of the 889,623 patients admitted to an  
45 ICU in 2020, 106,835 (12.0%) were diagnosed with COVID-19. There was substantial inter-  
46 registry variation in absolute COVID-19 admissions, and large variation in ICU admissions  
47 relative to the total community COVID-19 burden. Further detail can be found in the  
48 supplementary appendix.  
49  
50

#### 51 *Non-COVID-19 ICU admissions and demographics*

52 Compared with 2019, non-COVID-19 admissions in 2020 decreased by 9% from 859,854 to  
53 782,778. At the same time, beds included in the registries increased by 18.2% from 23,376 to  
54 27,638. Indexed to available beds, non-COVID-19 admissions per available ICU bed decreased  
55 by 12.5% in 2020 (range 33.9% decrease in admissions in CCA to 3.1% increase in New  
56 Zealand).  
57  
58

59 The international trends in non-COVID-19 admissions per million population differed  
60 substantially from the trends for COVID-19 admissions (Figures 1a and 1b respectively). Many

registries (Australia, New Zealand, Scotland, Finland, Netherlands, Japan, Argentina) had decreases in non-COVID-19 admissions of a similar magnitude to the increase in COVID-19 admissions, while some registries (Brazil, CCA, Uruguay) reported an increase in non-COVID-19 admissions in addition to COVID-19 admissions. However, when indexed to available beds, there was a decrease in non-COVID-19 admissions per million population in all registries except New Zealand (Figure 1c).

The mean age of non-COVID-19 patients was similar between the two years. The proportion of male patients increased slightly from 53.2% to 54.6% (range 52% in Brazil to 64% in Finland). All registries had a higher proportion of male patients in 2020 than 2019.

The proportion of non-COVID-19 patients receiving mechanical ventilation increased from 29.4% to 30.7%. Figure 1d shows rates of mechanical ventilation in non-COVID-19 patients by region and year. The overall increase in mechanical ventilation was primarily due to small increases in New Zealand, Denmark, the Netherlands, and Brazil.

Overall admission illness severity scores and predicted risk of death (expected hospital mortality) among non-COVID-19 patients were similar in 2019 and 2020 (see table 1).

#### *Non-COVID-19 ICU mortality*

Overall, non-COVID-19 patients experienced an increase in all-cause ICU mortality from 9.3% in 2019 to 10.4% in 2020, OR 1.15 (95% CI 1.14–1.17,  $p < 0.001$ ). This was consistent with a sensitivity analysis on those patients that received mechanical ventilation, with an increase in mortality from 22.8% to 23.9%, OR 1.04 (95% CI 1.03–1.05,  $p < 0.001$ ).

These findings differed greatly between regions (Supplementary Tables 1 and 2, Figure 2a). The odds ratio (OR) for ICU mortality for HICs was 0.96 (95% CI 0.94–0.98), compared to an OR of 1.25 (95% CI 1.23–1.26) for LMICs and HMICs ( $p < 0.001$  for between group differences) (Figure 3a).

For patients that received mechanical ventilation the trends were similar (Figure 2b) – HIC OR 0.97 (95% CI 0.95–0.99), LMIC and HMIC OR 1.06 (95% CI 1.05–1.07) ( $p < 0.001$  for between group differences) (Figure 3b).

#### Secondary outcomes

There was a similar increase in overall in-hospital all-cause mortality for non-COVID-19 patients and for those patients that received mechanical ventilation. Similarly to in-ICU mortality, there were significant international differences in in-hospital mortality, shown in Figure 2c. The OR for in-hospital mortality for HICs was 0.96 (95% CI 0.95–0.98), compared to 1.26 (95% CI 1.24–1.27) for HMICs ( $p < 0.001$ ). This was consistent in those patients that received mechanical ventilation, OR=0.96 (95% CI 0.94–0.98) for HICs, OR=1.10 (1.08–1.12) for HMICs ( $p < 0.001$ ). No data was available for LMICs.

In the six registries with complete data for hospital mortality and illness severity, the trends in observed ICU mortality are consistent with the Standardised Mortality Ratio (SMR) (Figure 2d), a risk-adjusted measure that incorporates disease severity.

Mean ICU length of stay for non-COVID-19 patients were similar (7.0 days in 2019 vs 7.2 days in 2020, while the mean hospital length of stay decreased from 14.9 days to 14.0 days ( $p < 0.001$ ).

#### **Discussion**

This study of aggregated data from over 1.7 million ICU admissions (including 1.64 million non-COVID-19 ICU admissions) from 15 countries found an increase in all-cause mortality of patients with non-COVID-19 diagnoses admitted to an intensive care unit in 2020 compared



1  
2 with 2019. Importantly, the overall increase in mortality was driven by an increase in mortality  
3 in middle-income countries (MICs; comprised of LMICs and HMICs), while mortality actually  
4 decreased in high-income countries in 2020 for non-COVID-19 patients. Similar findings were  
5 observed amongst patients that received mechanical ventilation. This is despite similar age,  
6 sex, illness severity, and mechanical ventilation rates between years.  
7

8 The SMRs followed the trends of crude mortality, with a large increase in Brazil (the only  
9 middle-income country with available SMR data), and stable ratios or small decreases in high-  
10 income countries. As SMR is calculated using an illness severity score and its derived predicted  
11 risk of death, this suggests that mortality changes were not the result of changes in illness  
12 severity in 2020, and other factors contributed.  
13

14 The causes of these findings are likely multifactorial, including ICU bed availability, healthcare  
15 practice and policy factors. Our data suggest an association between the COVID-19 ICU  
16 admission burden and non-COVID-19 outcomes. On average, HICs had a lower burden of  
17 COVID-19 than MICs (1.71 vs 4.01 admissions per bed, 21.62 vs 37.02 patient-days in ICU  
18 per bed). Brazil and the registry containing Bangladesh, India, Malaysia, Nepal, and Pakistan  
19 (CCA) who both experienced increases in mortality for non-COVID-19 patients, both had high  
20 rates of COVID-19 admissions per available ICU bed (4.2 and 5.7 respectively) and a high  
21 burden of care for COVID-19 patients as measured by patient-days in ICU per bed (51.5 and  
22 31.4 respectively). This is compared with Australia and New Zealand, which both had falls in  
23 mortality for non-COVID-19 patients and a lower burden of COVID-19, with 0.3 and 0.05  
24 COVID-19 admissions per ICU bed, and only 2.5 and 0.4 patient-days in ICU per bed  
25 respectively. Comparatively, the Netherlands also had a high burden of COVID-19, with 6.6  
26 admissions per bed and 81.6 patient-days in ICU per bed but had stable mortality for non-  
27 COVID-19 patients.  
28  
29  
30

31 Although such comparisons are limited by confounders such as country demographics and  
32 pandemic public health measures, it is plausible that greater healthcare system resourcing in  
33 the Netherlands compared with Brazil, Bangladesh, India, Malaysia, Nepal, and Pakistan  
34 provided pandemic capacity that influenced outcomes. This is supported by the large  
35 differences in GDP per capita (US\$; Netherlands: 52,397, Brazil: 6,797, CCA average: 3,329)<sup>21</sup>  
36 and healthcare expenditure as a proportion of GDP between the countries (Netherlands: 9.97%,  
37 Brazil: 9.51%, CCA average: 3.74%).<sup>22</sup> In addition to differences in funding, many MICs face  
38 additional challenges in providing critical care including inequitable regional distribution of  
39 ICUs, a high proportion of private ICU beds with a low proportion of the population with access  
40 to private healthcare, and lower staff-to-patient ratios.<sup>23</sup>  
41  
42  
43

44 Intrinsic differences in the design of critical care systems between countries likely also have  
45 an impact on ICU outcomes, including nurse-to-patient ratios in critical care units, thresholds  
46 for admission to ICU, and demographics of the broader community in each country. For  
47 example, an increase in the number of ICU patients per ICU nurse has been previously shown  
48 to be associated with increased mortality<sup>24</sup>, however few countries have mandatory minimum  
49 nursing ratios in critical care, and the usual nurse to patient ratio varies greatly (e.g., 1:1 for  
50 ventilated patients in Australia and New Zealand to 1:5 in Brazil)<sup>25</sup>. While nurse to patient  
51 ratios have an independent association with ICU mortality which may have impacted the  
52 observed changes in mortality in our study, ratios are also likely to be influenced by country  
53 income level, with high income countries having 11.4 nurses per 1000 members of the  
54 population, compared to 2.7 for middle-income countries.<sup>26</sup>  
55  
56  
57

58 A decrease in mortality for non-COVID-19 patients was observed in many registries in 2020  
59 however this was seen exclusively in high income countries. It is plausible that these health  
60

1  
2 systems were relatively under resourced prior to the pandemic, and that the positive mortality  
3 impact was a result of increased resourcing and health care expenditure in 2020 that  
4 outweighed the increased strain on intensive care. Comparatively, in MICs and low-income  
5 countries the additional ICU strain may have stretched systems unable to cope with the  
6 increased critical care demands of the pandemic. However further research is required to  
7 investigate this hypothesis.  
8

9  
10 Comparing our data to the Oxford COVID-19 Government Response Tracker (OxCGRT)  
11 shows little correlation between government responses and non-COVID-19 ICU mortality in  
12 2020. OxCGRT reports a Health and Containment Index based on 14 indicators of government  
13 response including “lockdown” style measures and healthcare investment, with a maximum  
14 index of 100 (the most stringent). Countries with high Health and Containment indices did not  
15 have improved non-COVID-19 ICU mortality in 2020 in this study. For example, Argentina  
16 had the highest average daily index in 2020 (63) and had an increase in ICU mortality  
17 (OR=1.13). Comparatively, Finland had the 2<sup>nd</sup> lowest index (36), while Australia had a high  
18 index (52) and both countries had decreases in ICU mortality (OR=0.8 and OR=0.96  
19 respectively). However, more stringent government responses during the pandemic have  
20 previously been associated with decreased COVID-19 mortality<sup>27</sup>, and it is possible that  
21 without stringent responses non-COVID-19 mortality would have been higher.  
22  
23

24 Another factor that may have influenced non-COVID-19 ICU mortality is the creation of  
25 additional ICU beds, through the subsequent requirement for altered staffing arrangements (e.g.  
26 staff new to critical care, decreased staff-to-patient ratios), and increased difficulty in  
27 maintaining quality assurance initiatives, as shown prior to the pandemic.<sup>28</sup> Brazil had a large  
28 increase in ICU bed capacity in 2020 with an increase of 21.2%, while the CCA and  
29 Argentinian ICUs had more modest increases of 1.8% and 4.4% respectively. Finland,  
30 Scotland, and Uruguay also had increases of 12-21%, while Australia, Japan, and the  
31 Netherlands had stable bed capacity. New Zealand, which had the lowest COVID-19 load, had  
32 a decrease in ICU bed capacity of 6.7%.  
33  
34

35 Total admissions per available bed fell in 2020, likely due in part to longer lengths of stay of  
36 COVID-19 patients increasing bed occupancy. Total patient-days per ICU bed are a better  
37 measure of ICU bed strain, and this increased in registries with a high burden of COVID-19  
38 (e.g. Brazil, the Netherlands) despite large decreases in non-COVID-19 patient-days per bed.  
39

40 The existing literature on the impact of the COVID-19 pandemic on international ICU  
41 outcomes is relatively limited. While many studies have been published on the characteristics  
42 and ICU outcomes of patients with COVID-19 within individual countries<sup>10-13</sup> these have been  
43 small and often single-centre studies. Relatively few studies have made international  
44 comparisons among these patients,<sup>8</sup> and reported mortality rates are highly variable. A number  
45 of studies have highlighted the difficulties in making international comparisons throughout the  
46 COVID-19 pandemic, including differing country demographics (e.g. age structure), COVID-  
47 19 testing practices and case definitions, definitions of COVID-19 deaths, access to healthcare,  
48 available ICU resources, and ICU admission and management practices.<sup>29, 30</sup> While one  
49 Argentinian study showed that the management of non-COVID-19 ICU patients had changed  
50 during the pandemic without altering outcomes,<sup>31</sup> and one Brazilian study demonstrated an  
51 increase in in-hospital mortality for non-COVID-19 patients in 2020,<sup>32</sup> to our knowledge this  
52 is the first international study comparing the outcomes of non-COVID-19 patients admitted to  
53 ICU during the COVID-19 pandemic. While the same difficulties of comparing outcomes exist  
54 as for COVID-19 patients, their impact is minimised in this study by comparing the change in  
55 mortality within each registry between 2019 and 2020.  
56  
57  
58  
59  
60

1  
2 A growing number of studies have been published on the observed excess death rate during the  
3 COVID-19 pandemic.<sup>6, 7, 33, 34</sup> The excess death rate observed in many countries has been  
4 attributed to COVID-19 infections, with underreporting and misidentifying COVID-cases used  
5 to explain the gap between COVID-19-related deaths and the excess death rate. However, this  
6 study suggests that the global excess death rate may also be partly due to a deterioration in  
7 health outcomes for non-COVID-19 patients. Furthermore, a number of studies on excess  
8 deaths have identified a decrease in overall country mortality during the pandemic, including  
9 in Australia, Denmark, Japan, New Zealand, and Uruguay,<sup>6, 7</sup> in keeping with the findings in  
10 this study. These studies have attributed the decrease in deaths in these countries to a decrease  
11 in non-COVID-19 infectious mortality and fewer road traffic accidents due to lockdowns.  
12  
13

14 A number of studies published prior to and during the COVID-19 pandemic have established  
15 associations between ICU strain and altered patient outcomes, including less adherence to  
16 evidence-based practices,<sup>28</sup> shorter times to initiating “do not resuscitate” orders,<sup>35</sup> and  
17 increased mortality.<sup>36</sup> During the pandemic increased ICU strain has also been associated with  
18 increased likelihood of interhospital transfer for ICU care,<sup>37</sup> and with increased mortality for  
19 both COVID-19 patients and non-COVID-19 patients.<sup>38</sup> Previously described associations  
20 between strain and mortality are consistent with the data described in this study.  
21  
22

23 The strengths of this study include use of international collaborative databases through the  
24 LOGIC-ICU initiative,<sup>17</sup> to facilitate the comparison of critical care outcomes between  
25 countries and the conduct of international critical care research. The study included over 1.7  
26 million admissions from 15 countries, with each registry containing data from a large group of  
27 participating hospitals.  
28

29 Limitations of the study include the use of aggregate data from each of the databases, limiting  
30 more detailed analysis. Data collection for each of the registries is not internationally  
31 standardised (e.g. different models of illness severity), and some registries were unable to  
32 provide complete data for this study. In some registries, the reported number of ICU beds in  
33 2020 did not include additional surge beds. The aggregated registry data precluded reporting  
34 combined medians for non-normally distributed variables (e.g., ICU length of stay), however  
35 reporting mean LOS provides a more accurate measure of resource utilisation. Additionally,  
36 the annualised data provided necessitated the assumption that all patients admitted in 2020  
37 were influenced by the pandemic, which may introduce bias, and precluded further analysis of  
38 the timing of COVID-19 outbreaks within countries, which may have had a significant impact  
39 on ICU strain. We were unable to access previous years of data to further examine the year-to-  
40 year variation in ICU mortality in these registries and cannot compare the observed change in  
41 mortality to a historical control.  
42  
43

44 The classification of COVID-19 cases required confirmed laboratory testing in all registries  
45 except the CCA registry, which included confirmed laboratory testing cases as well as  
46 clinically suspected COVID-19 cases. It is possible that some patients with COVID-19 may  
47 been inadvertently misclassified as non-COVID-19. Although this group is likely to be small,  
48 the impact of misclassification cannot be definitively determined. Cause of death was not  
49 reported, precluding further analysis. Finally, the relatively small national coverage of some  
50 registries (e.g. CCA, JIPAD) may limit the generalisability of the findings within some  
51 countries, and may introduce bias due to differences between participating and non-  
52 participating ICUs.  
53  
54

55 In summary, this study has demonstrated a global increase in non-COVID-19 ICU mortality  
56 during the pandemic. The impact on mortality has been highly variable between countries, with  
57 some countries experiencing large increases in mortality, and others experiencing a decrease  
58 in mortality. Many factors likely contribute to the direction and magnitude of the impact of the  
59  
60

1  
2 pandemic on mortality for non-COVID-19 patients, however country income level seems to  
3 have a strong influence. Further research conducted through international collaborative  
4 databases is vital to understanding and preventing further excess deaths.  
5

### 6 **Data Sharing**

7 Requests for data will be subject to the requirements and policies of each CQR. Requests  
8 should be directed to the corresponding author.  
9

### 10 **References**

- 11
- 12
- 13 1. Burrell AJ, Pellegrini B, Salimi F, Begum H, Broadley T, Campbell LT, et al.  
14 Outcomes for patients with COVID-19 admitted to Australian intensive care units during the  
15 first four months of the pandemic. *Med J Aust.* 2021;214(1):23-30.
- 16 2. Indian Registry of IntenSive c, KJ Adhikari N, Beane A, Devaprasad D, Fowler R,  
17 Haniffa R, et al. Impact of COVID-19 on non-COVID intensive care unit service utilization,  
18 case mix and outcomes: A registry-based analysis from India. *Wellcome Open Res.*  
19 2021;6:159.
- 20 3. Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh QD. Cancer  
21 Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. *JAMA Oncol.*  
22 2021;7(3):458-60.
- 23 4. Sharma V, Shaw A, Lowe M, Summers A, van Dellen D, Augustine T. The impact of  
24 the COVID-19 pandemic on renal transplantation in the UK. *Clin Med (Lond).*  
25 2020;20(4):e82-e6.
- 26 5. Elliott JM, Crozier IG. Decreases in cardiac catheter laboratory workload during the  
27 COVID-19 level 4 lockdown in New Zealand. *Intern Med J.* 2020;50(8):1000-3.
- 28 6. Karlinsky A, Kobak D. Tracking excess mortality across countries during the  
29 COVID-19 pandemic with the World Mortality Dataset. *Elife.* 2021;10.
- 30 7. Kontis V, Bennett JE, Rashid T, Parks RM, Pearson-Stuttard J, Guillot M, et al.  
31 Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19  
32 pandemic on all-cause mortality in 21 industrialized countries. *Nat Med.* 2020;26(12):1919-  
33 28.
- 34 8. Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with  
35 COVID-19: a systematic review and meta-analysis of observational studies. *Anaesthesia.*  
36 2020;75(10):1340-9.
- 37 9. Domecq JP, Lal A, Sheldrick CR, Kumar VK, Boman K, Bolesta S, et al. Outcomes  
38 of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The  
39 International Viral Infection and Respiratory Illness Universal Study Registry. *Crit Care*  
40 *Med.* 2021;49(3):437-48.
- 41 10. Dongelmans DA, Termorshuizen F, Brinkman S, Bakhshi-Raiez F, Arbous MS, de  
42 Lange DW, et al. Characteristics and outcome of COVID-19 patients admitted to the ICU: a  
43 nationwide cohort study on the comparison between the first and the consecutive upsurges of  
44 the second wave of the COVID-19 pandemic in the Netherlands. *Ann Intensive Care.*  
45 2022;12(1):5.
- 46 11. Ferrando C, Suarez-Sipmann F, Mellado-Artigas R, Hernandez M, Gea A, Arruti E, et  
47 al. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19  
48 are similar to other causes of ARDS. *Intensive Care Med.* 2020;46(12):2200-11.
- 49 12. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et  
50 al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19  
51 admitted to 920 German hospitals: an observational study. *Lancet Respir Med.*  
52 2020;8(9):853-62.  
53  
54  
55  
56  
57  
58  
59  
60

13. Richards-Belle A, Orzechowska I, Gould DW, Thomas K, Doidge JC, Mouncey PR, et al. COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern Ireland. *Intensive Care Med.* 2020;46(11):2035-47.
14. Bauer J, Bruggmann D, Klingelhofer D, Maier W, Schwettmann L, Weiss DJ, et al. Access to intensive care in 14 European countries: a spatial analysis of intensive care need and capacity in the light of COVID-19. *Intensive Care Med.* 2020;46(11):2026-34.
15. Kadri SS, Sun J, Lawandi A, Strich JR, Busch LM, Keller M, et al. Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020. *Ann Intern Med.* 2021;174(9):1240-51.
16. Listings of WHO's response to COVID-19: World Health Organisation; 2021 [17/2/2022]. Available from: <https://www.who.int/news/item/29-06-2020-covidtimeline>.
17. Dongelmans DA, Pilcher D, Beane A, Soares M, Del Pilar Arias Lopez M, Fernandez A, et al. Linking of global intensive care (LOGIC): An international benchmarking in critical care initiative. *J Crit Care.* 2020;60:305-10.
18. Population, total: The World Bank; 2021 [04/12/2021]. Available from: <https://data.worldbank.org/indicator/SP.POP.TOTL>.
19. Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). *Nat Hum Behav.* 2021;5(4):529-38.
20. Review Manager (RevMan). 5.4.1 ed: The Cochrane Collaboration; 2020.
21. GDP per capita (current US\$): World Bank; 2022 [05/02/2022]. Available from: <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD>.
22. Current health expenditure (% of GDP): World Bank; 2022 [05/02/2022]. Available from: <https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS>.
23. Salluh JIF, Lisboa T, Bozza FA. Challenges for the care delivery for critically ill COVID-19 patients in developing countries: the Brazilian perspective. *Crit Care.* 2020;24(1):593.
24. Chamberlain D, Pollock W, Fulbrook P, Group AWS. ACCCN Workforce Standards for Intensive Care Nursing: Systematic and evidence review, development, and appraisal. *Aust Crit Care.* 2018;31(5):292-302.
25. Soares M, Bozza FA, Angus DC, Japiassu AM, Viana WN, Costa R, et al. Organizational characteristics, outcomes, and resource use in 78 Brazilian intensive care units: the ORCHESTRA study. *Intensive Care Med.* 2015;41(12):2149-60.
26. Nurses and midwives (per 1,000 people): The World Bank; 2022 [cited 2022]. Available from: [https://data.worldbank.org/indicator/SH.MED.NUMW.P3?locations=XD-XP&name\\_desc=false](https://data.worldbank.org/indicator/SH.MED.NUMW.P3?locations=XD-XP&name_desc=false).
27. Hale T, Angrist N, Hale AJ, Kira B, Majumdar S, Petherick A, et al. Government responses and COVID-19 deaths: Global evidence across multiple pandemic waves. *PLoS One.* 2021;16(7):e0253116.
28. Weissman GE, Gabler NB, Brown SE, Halpern SD. Intensive care unit capacity strain and adherence to prophylaxis guidelines. *J Crit Care.* 2015;30(6):1303-9.
29. Millar JE, Busse R, Fraser JF, Karagiannidis C, McAuley DF. Apples and oranges: international comparisons of COVID-19 observational studies in ICUs. *Lancet Respir Med.* 2020;8(10):952-3.
30. Fitzpatrick P. The challenges of international comparisons of COVID-19. *Ir J Med Sci.* 2021;190(2):483-4.
31. Huespe IA, Marco A, Prado E, Bisso IC, Coria P, Gemelli N, et al. Changes in the management and clinical outcomes of critically ill patients without COVID-19 during the pandemic. *Rev Bras Ter Intensiva.* 2021;33(1):68-74.

- 1  
2 32. Zampieri FG, Bastos LSL, Soares M, Salluh JI, Bozza FA. The association of the  
3 COVID-19 pandemic and short-term outcomes of non-COVID-19 critically ill patients: an  
4 observational cohort study in Brazilian ICUs. *Intensive Care Med.* 2021;47(12):1440-9.  
5 33. Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L, Taylor DDH. Excess  
6 Deaths From COVID-19 and Other Causes, March-July 2020. *JAMA.* 2020;324(15):1562-4.  
7 34. Weinberger DM, Chen J, Cohen T, Crawford FW, Mostashari F, Olson D, et al.  
8 Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States,  
9 March to May 2020. *JAMA Intern Med.* 2020;180(10):1336-44.  
10 35. Hua M, Halpern SD, Gabler NB, Wunsch H. Effect of ICU strain on timing of  
11 limitations in life-sustaining therapy and on death. *Intensive Care Med.* 2016;42(6):987-94.  
12 36. Bihari S, McElduff P, Pearse J, Cho O, Pilcher D. Intensive care unit strain and  
13 mortality risk in patients admitted from the ward in Australia and New Zealand. *J Crit Care.*  
14 2022;68:136-40.  
15 37. Pilcher DV, Duke G, Rosenow M, Coatsworth N, O'Neill G, Tobias TA, et al.  
16 Assessment of a novel marker of ICU strain, the ICU Activity Index, during the COVID-19  
17 pandemic in Victoria, Australia. *Critical Care and Resuscitation.* 2021;23(3):300-7.  
18 38. Wilcox ME, Rowan KM, Harrison DA, Doidge JC. Does Unprecedented ICU  
19 Capacity Strain, As Experienced During the COVID-19 Pandemic, Impact Patient Outcome?  
20 *Crit Care Med.* 2022;50(6):e548-e56.  
21  
22  
23  
24  
25  
26  
27  
28  
29

### Contributors

30 DP, EL, and JS conceived the study and developed the study design. Data was collected and  
31 provided by DP, EL, JS, AB, DA, MBMN, SB, GB, SC, CC, DD, AF, AG, RoH, RaH, MH,  
32 SH, NI, BKT, NL, MPAL, HO, DP, MR and MS. JM and DP accessed and verified the  
33 data. JM analysed the data, with assistance from DP and MB. JM, DP, EL, and JS wrote the  
34 initial draft, and all authors were involved in commenting on subsequent revisions.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1: Non-COVID-19 ICU admissions in 2019 and 2020**

	<b>Global 2019</b>	<b>Global 2020</b>	<b>Effect size</b>	<b>95% CI</b>	<b>P value</b>
<b>ICU Admissions</b>					
Total (n)	859854	782788			
Elective Surgical	27.1%	25.8%	OR = 0.92	0.91 – 0.92	p < 0.001
Emergency Surgical	9.4%	9.8%	OR = 1.03	1.02 – 1.04	p < 0.001
Medical	48.6%	48.8%	OR = 1.01	1.00 – 1.01	p = 0.053
No information	14.9%	15.4%	OR = 1.34	1.32 – 1.35	p < 0.001
<b>Age</b>					
Years (SD)	61.4 (19.4)	61.2 (19.1)	MD = -0.17	-0.11 – -0.23	p < 0.001
<b>Sex</b>					
Male	53.2%	54.6%	OR = 1.06	1.05 – 1.07	p < 0.001
<b>Mechanical Ventilation (MV)</b>	29.4%	30.7%	OR = 1.08	1.07 – 1.08	p < 0.001
<b>Illness Severity</b>					
APACHE II Score - mean (SD) *	16.1 (8.6)	16.1 (8.1)	MD = -0.01	-0.05 – 0.04	p = 0.79
SOFA Score - mean (SD) †	3.1 (3.3)	3.1 (3.4)	MD = 0.08	0.07 – 0.09	p < 0.001
SAPS 3 Score - mean (SD) ‡	43.9 (16.8)	44.0 (16.7)	MD = 0.05	-0.02 – 0.12	p = 0.15
Predicted Risk of Death - % (SD)	14.5 (19.9)	14.6 (20.0)	MD = 0.02	-0.04 – 0.08	p = 0.59
<b>Length of Stay (mean)</b>					
ICU - mean days (SD)	4.7 (11.4)	4.7 (9.1)	MD = -0.03	-0.06 – -0.01	p = 0.004
Hospital - mean days (SD)	14.9 (58.2)	14.0 (48.2)	MD = -0.69	-0.78 – -0.59	p < 0.001
<b>ICU Mortality</b>					

1	ICU - all % (n)	9·27% (839066)	10·42% (758925)	OR = 1.15	1.14 – 1.17	p < 0.001
2	[95% Confidence Interval]	[9·21 - 9·34%]	[10·35 – 10·48%]			
3	ICU - if received MV % (n)	22·80% (249808)	23·91% (235584)	OR = 1.04	1.03 – 1.05	p < 0.001
4	[95% Confidence Interval]	[22·63 – 22·96%]	[23·73 – 24·08%]			
5	<b>Hospital Mortality</b>					
6						
7	Hospital – all % (n)	13·01% (749283)	14·52% (677468)	OR = 1.15	1.14 – 1.16	p < 0.001
8	[95% Confidence Interval]	[12·94 – 13·09%]	[14·44 – 14·61%]			
9	Hospital - if received MV % (n)	32·16% (182985)	33·62% (176604)	OR = 1.05	1.03 – 1.06	p < 0.001
10	[95% Confidence Interval]	[31·94 – 32·37%]	[33·40 – 33·84%]			

\* Includes data from Aus, NZ, Argentina, Finland, CCA

† Includes data from Aus, NZ, Brazil, Finland, Japan, Netherlands

‡ Includes data from Brazil, Uruguay, Denmark

OR: Odds ratio; MD: Mean Difference.



Figure 1a: Non-COVID-19 ICU Admissions per million members of the population




Figure 1c: Non-COVID-19 ICU Admissions per million members of the population, indexed to available beds




Figure 1b: COVID-19 ICU Admissions per 1M members of the population




Figure 1d: Proportion of Non-COVID-19 patients receiving mechanical ventilation




Figure 2a: Non-COVID-19 In-ICU Mortality




Figure 2c: Non-COVID-19 In-Hospital Mortality for patients that received mechanical ventilation




Figure 2b: Non-COVID-19 In-ICU Mortality for patients that received mechanical ventilation





Figure 2d: Non-COVID-19 Standardised Mortality Ratio




al: For P

**Figure 3a: Non-COVID-19 ICU Mortality, by Country Income Level**



**Figure 3b: Non-COVID-19 ICU Mortality if received mechanical ventilation, by Country Income Level**



Supplementary Table 1: Characteristics of patients admitted to ICU in 2019 with Non-COVID-19 diagnoses

	Australasia		Europe				Asia		South America		
	Australia	New Zealand	Scotland	Finland	Denmark	Netherlands	Japan	CCA	Argentina	Brazil	Uruguay
<b>ICUs in registry</b>	168	18	24	26	40	81	57	58	78	1469	21
<b>ICU beds in registry</b>	2286	268	252	268	..	1150	666	746	808	16757	175
<b>Admissions</b>											
Total (n)	179735	15342	16494	19945	27837	73959	48495	20684	24580	428906	3877
Per Million Population (n)	7538	4599	3024	3802	4788	4264	2534	435	6949	3855	2667
Per available ICU bed	78.62	57.25	65.45	74.42	..	64.31	72.82	27.73	30.42	25.60	22.15
<b>Age</b>											
Years (SD)	62.5 (17.9)	57.4 (19.6)	..	57.1 (21.2)	60.6 (21.3)	62.8 (15.9)	63.5 (21.3)	50.7 (21.6)	..	61.5 (19.7)	59 (19.2)
<b>Sex</b>											
Male	56%	60%	..	64%	60%	61%	61%	56%	..	50%	59%
<b>Mechanical Ventilation (MV)</b>											
	31%	44%	55%	62%	46%	47%	38%	38%	31%	21%	47%
<b>Illness Severity</b>											
APACHE II Score - mean (SD)	15.0 (7.3)	16.0 (7.8)	..	18.3 (8.3)	..	..	..	20.9 (7.9)	18.1 (14.8)	..	..
SOFA Score - mean (SD)	3.7 (2.8)	4.2 (2.9)	..	6.1 (3.4)	..	5.9 (3.9)	4.9 (3.6)	..	..	1.9 (2.8)	..
SAPS 3 Score - mean (SD)	..	..	..	..	58.5 (19.7)	..	..	..	..	42.9 (16.1)	50.3 (18.7)
Predicted Risk of Death - % (SD)	8.3 (15.8)	10.7 (18.4)	..	20.4 (23.3)	..	20.0 (20.0)	..	32.1 (23.8)	17.2 (22.1)	14.9 (19.9)	24.5 (25.9)
<b>Length of Stay (mean)</b>											
ICU - mean days (SD)	3.0 (5.1)	2.9 (6.1)	4.1 (6.6)	3.2 (5.3)	3.2 (24.8)	3.1 (6.9)	4.5 (6.8)	3.9 (6.6)	6.9 (16.6)	5.8 (13.0)	7.0 (20.7)
ICU – median days (IQR)	1.7 (2.2)	1.4 (2.0)	2 (2.1)	1.6 (2.4)	1.2 (2.7)	1.1 (2.0)	2.0 (3.0)	2.0 (3.0)	3.0 (4.3)	3.0 (5.0)	3.0 (6.0)
Hospital - mean days (SD)	15.2 (80.2)	14.5 (88.6)	16.2 (23.7)	12.6 (15.9)	..	13.5 (110.8)	35.4 (51.5)	..	..	12.8 (27.0)	16.3 (31.6)
Hospital – median days (IQR)	7.9 (10.8)	8.1 (11.5)	9.0 (14.0)	8.0 (10.0)	..	8.0 (9.0)	21 (26)	..	..	7.0 (9.0)	8.0 (15)
<b>In-ICU Mortality</b>											
Non-COVID-19 – All % (n)	4.6% (7937)	7.5% (1099)	11.4% (1880)	4.7% (942)	10.9% (3046)	9.3% (6876)	3.8% (1821)	17.5% (3600)	16.5% (4065)	11% (45847)	19.1% (705)
Non-COVID-19 – If received MV % (n)	10.3% (5471)	13.3% (859)	17.5% (1587)	7.1% (870)	16.2% (2089)	15.4% (5396)	8.2% (1526)	28.5% (2182)	40.2% (3010)	39.0% (33362)	35.1% (600)
<b>In-Hospital Mortality</b>											
Non-COVID-19 – all % (n)	7.2% (12360)	10.3% (1507)	14.4% (2381)	8.3% (1664)	..	12.8% (9484)	8.6% (4158)	..	..	16.2% (65096)	23.5% (841)
Non-COVID-19 – if received MV % (n)	13.1% (6938)	15.7% (1014)	20.6% (1871)	11.6% (1424)	..	..	15.0% (2857)	..	..	53.8% (44050)	40.9% (685)

.. indicates data not available

\*The CCA registry includes ICUs from Bangladesh, India, Malaysia, Nepal, and Pakistan  
OR: Odds ratio; MD: Mean Difference; IQR: Inter-quartile Range

	Australasia		Europe				Asia		South America		
	Australia	New Zealand	Scotland	Finland	Denmark	Netherlands	Japan	CCA	Argentina	Brazil	Uruguay
<b>ICUs in registry</b>	173	18	23	26	41	81	70	102	58	1469	21
<b>ICU beds in registry</b>	2346	250	280	302	..	1150	830	1336	627	20304	213
<b>Admissions</b>											
Total (n)	174302	14759	12797	18638	25839	60359	43773	24494	14003	389353	4471
Per Million Population (n)	7219	4333	2346	3547	4431.01	3461	1868	508	5273	5179	3248
Per available ICU bed	74.30	59.04	45.70	61.72	..	52.49	52.74	18.33	22.33	19.18	20.99
<b>Age</b>											
Years (SD)	62.1 (17.9)	58.3 (18.7)	..	56.7 (21.1)	61 (20.7)	62.6 (15.9)	64.5 (20.4)	50.1 (20.4)	..	61.3 (19.4)	58.8 (19.7)
<b>Sex</b>											
Male	56%	61%	..	64%	60%	62%	61%	58%	..	52%	60%
<b>Mechanical Ventilation (MV)</b>											
	30%	45%	51%	60%	47%	49%	39%	36%	30%	23%	45%
<b>Illness Severity</b>											
APACHE II Score - mean (SD)	15.0 (7.2)	15.7 (7.5)	..	18.0 (8.3)	..	..	..	22.6 (8.4)	16.6 (11.7)	..	..
SOFA Score - mean (SD)	3.7 (2.8)	4.2 (2.9)	..	6.0 (3.4)	..	6.1 (3.9)	5.0 (3.7)	..	..	2.0 (3.0)	..
SAPS 3 Score - mean (SD)	..	..	..	..	57.5 (21.5)	..	..	..	..	43.0 (15.9)	49.6 (18.5)
Predicted Risk of Death - % (SD)	8.1 (15.7)	9.6 (17.2)	..	19.5 (22.8)	..	20.0 (20.0)	..	35.5 (24.8)	18.6 (21.2)	15.0 (19.9)	23.6 (25.1)
<b>Length of Stay (mean)</b>											
ICU - mean days (SD)	2.9 (4.7)	2.9 (5.8)	3.9 (6.3)	3.0 (4.8)	3.4 (6.7)	3.0 (7.0)	4.4 (6.0)	4.0 (7.5)	7.7 (13.0)	6.0 (11.1)	6.6 (13.7)
ICU – median days (IQR)	1.7 (2.2)	1.6 (2.0)	2 (3.2)	1.5 (2.2)	1.2 (2.5)	1.0 (1.8)	2.0 (3.0)	2.0 (3.0)	3.0 (5.0)	3.0 (5.0)	3.0 (6.0)
Hospital - mean days (SD)	13.9 (85)	14.7 (106.9)	15.7 (20.9)	11.9 (16.5)	..	12.8 (16.6)	32.7 (42.5)	12.9 (12.4)	..	12.2 (21.0)	13.6 (19.5)
Hospital – median days (IQR)	7.8 (10.5)	8.1 (11.3)	9.0 (14)	8.0 (10)	..	7.9 (9.0)	21 (24)	8.0 (16)	..	7.0 (9.0)	7.0 (13)
<b>In-ICU Mortality</b>											
Non-COVID-19 – all % (n)	4.3% (7156)	6.5% (910)	11.6% (1486)	4.1% (760)	11% (2845)	9.2% (5542)	3.9% (1701)	22.6% (5454)	19.4% (2714)	13.2% (49734)	18.2% (744)
Non-COVID-19 – if received MV % (n)	9.9% (5029)	11.7% (740)	19.6% (1265)	5.6% (694)	16.3% (1972)	14.9% (4415)	8.3% (1409)	38.7% (3263)	45.3% (1928)	40.5% (35021)	31.8% (584)
<b>In-Hospital Mortality</b>											
Non-COVID-19 – all % (n)	6.8% (11208)	8.9% (1248)	15.6% (2000)	7.3% (1366)	..	12.9% (7791)	8.5% (3699)	30.1% (7271)	..	19.6% (70197)	23.4% (880)
Non-COVID-19 – if received MV % (n)	12.6% (6378)	14.2% (900)	23.7% (1530)	9.2% (1132)	..	..	15% (2567)	51.8% (4366)	..	56.2% (46201)	38.9% (662)

.. indicates data not available

\*The CCA registry includes ICUs from Bangladesh, India, Malaysia, Nepal, and Pakistan  
OR: Odds ratio; MD: Mean Difference; IQR: Inter-quartile Range

1  
2  
3  
4  
5 **Supplementary Appendix**  
6  
7

8 **Table of Contents**  
9

10 Information on participating registries.....1  
11  
12 Information on Expected In-Hospital Mortality.....1  
13  
14  
15 Supplementary Table 1: Characteristics of participating registries.....3  
16  
17  
18 Supplementary Figure 1: COVID-19 ICU admissions in 2020.....4  
19  
20  
21 References for supplementary appendix .....5  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Confidential: For Review Only

### Information on participating registries

Data from Argentina was provided by the Argentine Society of Intensive Care/Sociedad Argentina de Terapia Intensiva (SATI) from the national registry, SATI-Q. Further information can be found at <https://www.satiq.net.ar/>

Data from Australia and New Zealand was provided by the Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcome and Resource Evaluation, which runs the bi-national CQR. Further information can be found at <https://www.anzics.com.au/anzics-registries/>

Data from Brazil was provided by the Brazilian Society of Intensive Care (AMIB) and Epimed Solutions which run the national registry UTIs Brasileiras. Further information can be found at <http://www.utisbrasileiras.com.br/>

Data from Denmark was provided by the national Danish Intensive Care Database (DID). Further information can be found at <https://pubmed.ncbi.nlm.nih.gov/27822095/>

Data from Finland was provided by the Finnish Intensive Care Consortium (FICC), which run the national database – BM-ICU (maintained by TietoEvry).

Data from Japan was provided by the Japanese Society of Intensive Care Medicine (JSICM) from the national database JIPAD (Japanese Intensive care PATient Database). Further information can be found at <https://www.jipad.org/en>

Data from the Netherlands was National Intensive Care Evaluation (NICE) foundation, which runs the national NICE registry. Further information can be found at <http://www.stichting-nice.nl/>

Data from Scotland was provided by the Scottish Intensive Care Society (SICS) Audit Group which runs the national CQR – SICSAG. Further information can be found at <https://www.sicsag.scot.nhs.uk/>

Data from Uruguay was provided by the Uruguayan Society of Intensive Care Medicine/ Sociedad Uruguaya de Medicina Intensiva (SUMI) and Epimed Solutions which run the national registry UCIs Uruguayas. Further information can be found at <http://www.ucisuruguayas.com.uy>

Data from Bangladesh, India, Malaysia, Nepal and Pakistan was provided by the Collaboration for Research, Implementation and Training in Intensive Care in Asia network through the CRIT CARE ASIA (CCA) registry. <https://www.tropmedres.ac/units/moru-bangkok/malaria/critical-illness>

### Information on Expected In-Hospital Mortality

Each CQR uses its own local calibration of their chosen illness severity model to calculate the predicted in hospital mortality. Each CQR uses the predicted mortality for benchmarking ICUs with their relevant region, and the illness severity models are periodically re-calibrated to ensure ongoing validity. An example of the methodology can be found here:

Moralez, G. M., Rabello, L. S. C. F., Lisboa, T. C., Lima, M. D. F. A., Hatum, R. M., De Marco, F. V. C., Alves, A., Pinto, J. E. D. S. S., de Araújo, H. B. N., Ramos, G. V., Silva, A. R., Fernandes, G. C., Faria, G. B. A., Mendes, C. L., Ramos Filho, R. Á., de Souza, V. P., do Brasil, P. E. A. A., Bozza, F. A., Salluh, J. I. F., Soares, M., ... ORCHESTRA Study Investigators (2017). External validation of SAPS 3 and MPM0-III scores in 48,816 patients from 72 Brazilian ICUs. *Annals of intensive care*, 7(1), 53. <https://doi.org/10.1186/s13613-017-0276-3>

Some CQRs have developed their own models of predicted in-hospital mortality (e.g. ANZROD in Australia and New Zealand, JROD in Japan). These models were created and are maintained for the purpose of comparing outcomes between ICUs within each CQR. An example of the methodology used in creating these models can be found here:

Endo, H., Uchino, S., Hashimoto, S. et al. Development and validation of the predictive risk of death model for adult patients admitted to intensive care units in Japan: an approach to improve the accuracy of healthcare quality measures. *J intensive care* 9, 18 (2021). <https://doi.org/10.1186/s40560-021-00533-z>

The expected (or predicted) in hospital mortality calculated using either of the above models then provides an estimate of the risk of death during hospital admission. By comparing the expected in-hospital mortality rate with the observed mortality rate, it can be calculated whether there were more or fewer deaths than expected – i.e. the standardised mortality ratio (SMR).  $SMR = \text{number of observed deaths} / \text{number of expected deaths}$ . When the  $SMR < 1$  fewer deaths than expected occurred, and when the  $SMR > 1$  more deaths than expected occurred. As the expected mortality rate is calculated from models that incorporate illness severity, when more deaths than expected occur, it is likely that factors other than illness severity have influenced the observed mortality rate.



**Table 1: Characteristics of participating ICU registries**

Country / Region	Data source (registry name)	Population	ICUs in registry (n)				2020 Coverage (% total ICUs)	Public ICUs (%)	Individual records (n)	Illness severity model (s)						
			2019	2020	2019	2020				APACHE II	APACHE III	SOFA	SAPS 2	SAPS 3	Local Model	Model for Expected In-Hospital Mortality
Asia*	CCA*	1827.1M	58	102	746	1336	1.34% <sup>†</sup>	61%	52830	x						APACHE II
Argentina	SATI-Q	45.4M	78	58	808	627	5.85% <sup>‡</sup>	45%	40104	x						APACHE II
Australia	ANZICS	25.7M	168	173	2286	2346	94.0%	81%	361400	x	x	x			x	ANZROD - local model
Brazil	UTIs Brasileiras	212.6M	1469	1469	16757	20304	35.4%	62%	888223			x		x		SAPS 3
Denmark	DID	5.8M	40	41	..	..	100%	100%	54804					x		SAPS 3
Finland	FICC	5.5M	26	26	268	302	95.0%	100%	35363	x		x	x		x	SAPS 2
Japan	JIPAD	125.8M	57	70	666	830	18.6%	70%	93239	x	x	x		x	x	JROD – local model
Netherlands	NICE Registry	17.4M	81	81	1150	1150	100%	100%	141883		x	x				APACHE III
New Zealand	ANZICS	5.1M	18	18	268	250	67.0%	94%	29055	x	x	x			x	ANZROD - local model
Scotland	SICSAG	5.5M	24	23	252	280	100%	100%	29497	x						APACHE II
Uruguay	UCIs Uruguayas	3.5M	21	21	175	213	39.6%	19%	8156					x		SAPS 3

.. indicates data not available


\*The CCA registry includes ICUs from Bangladesh, India, Malaysia, Nepal, and Pakistan

<sup>†</sup> CCA coverage is based on % of national bed coverage as opposed to % of ICUs coverage. Coverage calculated from previously published data from Bangladesh<sup>1</sup>, India<sup>2</sup>, Malaysia<sup>3</sup>, Nepal<sup>4</sup>, and Pakistan<sup>5</sup>

<sup>‡</sup> Calculated from data published by the Ministry of Health, Argentina<sup>6</sup>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Supplementary Figure 1: COVID-19 ICU admissions in 2020



Initial: For Review Only

## References

1. Mostafa N. Critical Care Medicine: Bangladesh Perspective. *Adv J Emerg Med.* 2018;2(3):e27.
2. Kapoor G, Hauck S, Sriram A, Joshi J, Schueller E, Frost I, et al. [PREPRINT] State-wise estimates of current hospital beds, intensive care unit (ICU) beds and ventilators in India: Are we prepared for a surge in COVID-19 hospitalizations? 2020.
3. Jayasundara P, Peariasamy KM, Law KB, Abd Rahim KNK, Lee SW, Ghazali IMM, et al. Sustaining effective COVID-19 control in Malaysia through large-scale vaccination. *Epidemics.* 2021;37:100517.
4. Acharya SP. Critical care medicine in Nepal: where are we? *Int Health.* 2013;5(2):92-5.
5. Hashmi M, Taqi A, Memon MI, Ali SM, Khaskheli S, Sheharyar M, et al. A national survey of critical care services in hospitals accredited for training in a lower-middle income country: Pakistan. *J Crit Care.* 2020;60:273-8.
6. List of Health Establishment settled in the federal registry - January 2021: Argentinian Ministry of Health; [Available from: [https://datos.gob.ar/vi/dataset/salud-listado-establecimientos-salud-asetados-registro-federal-refes/archivo/salud\\_cccd5cbd-af97-484f-82e5-7d40e3b358d5](https://datos.gob.ar/vi/dataset/salud-listado-establecimientos-salud-asetados-registro-federal-refes/archivo/salud_cccd5cbd-af97-484f-82e5-7d40e3b358d5)].